Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Phys Rev Lett ; 127(13): 131802, 2021 Sep 24.
Artigo em Inglês | MEDLINE | ID: mdl-34623867

RESUMO

Searches for the lepton number violating K^{+}→π^{-}µ^{+}e^{+} decay and the lepton flavor violating K^{+}→π^{+}µ^{-}e^{+} and π^{0}→µ^{-}e^{+} decays are reported using data collected by the NA62 experiment at CERN in 2017-2018. No evidence for these decays is found and upper limits of the branching ratios are obtained at 90% confidence level: B(K^{+}→π^{-}µ^{+}e^{+})<4.2×10^{-11}, B(K^{+}→π^{+}µ^{-}e^{+})<6.6×10^{-11} and B(π^{0}→µ^{-}e^{+})<3.2×10^{-10}. These results improve by 1 order of magnitude over previous results for these decay modes.

2.
Pediatr Med Chir ; 16(1): 93-4, 1994.
Artigo em Italiano | MEDLINE | ID: mdl-8029101

RESUMO

The Authors describe a case of congenital coagulation factor V deficiency with severe prenatal intraventricular hemorrhage. Factor V is an essential enzyme catalysing the process of thrombin generation. Low levels of enzyme were also found in both parents, who demonstrate subclinic alterations of coagulation parameters. The severe deficiency of factor V in the newborn (8%) caused frequent and severe intracranial and gastric hemorrhages that brought newborn to death in few weeks.


Assuntos
Hemorragia Cerebral/etiologia , Deficiência do Fator V , Doenças Fetais , Testes de Coagulação Sanguínea , Deficiência do Fator V/complicações , Deficiência do Fator V/diagnóstico , Hemorragia Gastrointestinal/etiologia , Hematoma Subdural/etiologia , Humanos , Recém-Nascido , Imageamento por Ressonância Magnética , Masculino
3.
Pediatr Med Chir ; 13(5): 519-22, 1991.
Artigo em Italiano | MEDLINE | ID: mdl-1788114

RESUMO

The Authors describe a case of William-Beuren Syndrome, also know as "Fanconi-Schlesinger Syndrome" or "Idiopathic Hypercalcaemia, supravalvular aortic stenosis, elfin facies syndrome". Irritability and chronic constipation are early features. Hypercalcaemia may occur in infancy but rarely after 1 year age. The facies is characteristic. Supravalvular aortic stenosis is the most frequent cardiac abnormality. Other common features are short stature, mental retardation and significant behavioural disorders. In this case report typical facies, short stature, behavioural disorders are associated with epilepsy in early years of life. Hypercalcaemia or cardiovascular malformation were not found.


Assuntos
Estenose da Valva Aórtica/congênito , Face/anormalidades , Estenose da Valva Aórtica/diagnóstico , Humanos , Recém-Nascido , Masculino , Síndrome
4.
Pediatr Med Chir ; 11(4): 467-9, 1989.
Artigo em Italiano | MEDLINE | ID: mdl-2694110

RESUMO

A case of Hypohidrotic Ectodermal Dysplasia is reported. Inability of sweating is associated with characteristic craniofacial anomalies, oligo-anodontia and rare, thin hair. X-linked and autosomal inheritance are both supposed.


Assuntos
Displasia Ectodérmica/genética , Anodontia , Humanos , Lactente , Masculino , Fenótipo , Síndrome
5.
Eur J Clin Pharmacol ; 34(1): 25-8, 1988.
Artigo em Inglês | MEDLINE | ID: mdl-3282894

RESUMO

The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.


Assuntos
Anticolesterolemiantes/administração & dosagem , Fenofibrato/administração & dosagem , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hipolipemiantes/administração & dosagem , Lipoproteínas/sangue , Propionatos/administração & dosagem , Adulto , Anticolesterolemiantes/sangue , Anticolesterolemiantes/farmacocinética , Anticolesterolemiantes/uso terapêutico , Cápsulas , Ensaios Clínicos como Assunto , Esquema de Medicação , Feminino , Fenofibrato/análogos & derivados , Fenofibrato/sangue , Fenofibrato/farmacocinética , Fenofibrato/uso terapêutico , Humanos , Hiperlipoproteinemia Tipo II/sangue , Hipolipemiantes/sangue , Hipolipemiantes/farmacocinética , Hipolipemiantes/uso terapêutico , Masculino , Pessoa de Meia-Idade , Cooperação do Paciente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...